A detailed history of Vanguard Group Inc transactions in In8 Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,423,897 shares of INAB stock, worth $355,974. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,423,897
Previous 1,423,897 -0.0%
Holding current value
$355,974
Previous $1.21 Million 68.26%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$0.95 - $1.69 $956,840 - $1.7 Million
1,007,201 Added 241.71%
1,423,897 $1.68 Million
Q4 2023

Feb 14, 2024

BUY
$0.69 - $2.34 $53,797 - $182,445
77,968 Added 23.02%
416,696 $575,000
Q3 2023

Nov 14, 2023

BUY
$0.92 - $1.74 $47,068 - $89,020
51,161 Added 17.79%
338,728 $352,000
Q2 2023

Aug 14, 2023

BUY
$1.05 - $3.24 $81,371 - $251,090
77,497 Added 36.89%
287,567 $442,000
Q1 2023

May 15, 2023

BUY
$1.17 - $2.83 $48,454 - $117,201
41,414 Added 24.56%
210,070 $273,000
Q4 2022

Feb 10, 2023

SELL
$1.39 - $2.47 $1,212 - $2,153
-872 Reduced 0.51%
168,656 $389,000
Q3 2022

Nov 14, 2022

BUY
$1.77 - $2.89 $104,134 - $170,027
58,833 Added 53.15%
169,528 $342,000
Q2 2022

Aug 12, 2022

SELL
$2.02 - $4.68 $1,611 - $3,734
-798 Reduced 0.72%
110,695 $250,000
Q1 2022

May 13, 2022

SELL
$2.76 - $4.6 $24,075 - $40,125
-8,723 Reduced 7.26%
111,493 $372,000
Q4 2021

Feb 14, 2022

BUY
$4.39 - $8.55 $31,239 - $60,841
7,116 Added 6.29%
120,216 $528,000
Q3 2021

Nov 12, 2021

BUY
$6.71 - $10.0 $758,901 - $1.13 Million
113,100 New
113,100 $775,000

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $6.13M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.